Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
The development of tumor necrosis factor alpha (TNF-) inhibitors is probably one of the most significant advancement in the management of a number of inflammatory rheumatic disorders to date. High efficacy of the treatment is associated with relatively rare and very heterogeneous adverse reactions....
Guardado en:
Autores principales: | Eugeniusz Józef Kucharz, Anna Kotulska-Kucharz |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c12f29a7f5784476be57d07b8b576008 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Medical eponyms from linguistic and historical points of view
por: Eugeniusz Józef Kucharz
Publicado: (2020) -
Osseous manifestations of sarcoidosis
por: Eugeniusz Józef Kucharz
Publicado: (2020) -
In memoriam of Professor Anatol Święcicki
por: Maria Maślińska, et al.
Publicado: (2020) -
Clinical manifestations of Whipple’s disease mimicking rheumatic disorders
por: Eugeniusz J. Kucharz, et al.
Publicado: (2021) -
The Effect of Phototherapy on Serum Level of Tumor Necrosis Factor Alpha in Neonates
por: Mohamed Neam, et al.
Publicado: (2020)